Prior to the initiation of intravenous bisphosphonate therapy for osteoporosis, the impact on ocular health is not routinely discussed with patients. This is due to the scarcity of data on the association between bisphosphonates and ocular side effects, resulting in lack of provider awareness to effectively counsel patients. Furthermore, there is little consensus among clinicians on the safety of re-challenging with intravenous bisphosphonate treatment following ocular complications. This is a case report of a patient who developed orbital inflammation four days after receiving a zoledronate infusion. This case was discussed amongst health care providers and osteoporosis experts during a meeting of Bone Health Extension for Community Healthcare Outcomes (ECHO) virtual platform, which was established in 2015.
Keyphrases
- healthcare
- case report
- end stage renal disease
- bone mineral density
- public health
- mental health
- newly diagnosed
- ejection fraction
- oxidative stress
- health information
- postmenopausal women
- prognostic factors
- primary care
- peritoneal dialysis
- type diabetes
- palliative care
- computed tomography
- machine learning
- skeletal muscle
- social media
- risk factors
- smoking cessation
- diffusion weighted
- bone regeneration
- insulin resistance